NCT03469895

Autoimmune Cytopenia and BcR Inhibitors

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

Detailed description

The investigators of the study propose a card of data collection, validated by the scientific council of the group FILO. The data to be collected are entered on an e-CRF made available to the investigators on a secure site. The main data collected are as follows * anonymized demographic data * Clinical and Biological Data of CLL at Diagnosis * Previous treatments of LLC and CAI * clinical and laboratory data at the time of initiation of BCRi treatment * response to treatment with BCRi * tolerance to BCRi treatment * Progression under treatment with BCRi * Recent news

Conditions

• Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia

Interventions

Type	Name	Description
DRUG	ibrutinib ou idelalisib	treatment by ibrutinib or idelalisib for autoimmune cytopenia

Timeline

• Start date: 2017-07-21
• Primary completion: 2018-07-01
• Completion: 2018-07-01
• First posted: 2018-03-19
• Last updated: 2018-03-19

Locations

1 site across 1 country: France